# ProSpecTive sAmpling in dRiver muTation Pulmonary Oncology Patients on Tyrosine Kinase Inhibitors (START-TKI)

> **NCT05221372** · — · RECRUITING · sponsor: **Erasmus Medical Center** · enrollment: 1300 (estimated)

## Conditions studied

- Non Small Cell Lung Cancer
- Liquid Biopsy
- Tyrosine Kinase Inhibitor

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05221372
- **Lead sponsor:** Erasmus Medical Center
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2017-02-02
- **Primary completion:** 2031-01-01
- **Final completion:** 2031-01-01
- **Target enrollment:** 1300 (ESTIMATED)
- **Last updated:** 2022-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05221372

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05221372, "ProSpecTive sAmpling in dRiver muTation Pulmonary Oncology Patients on Tyrosine Kinase Inhibitors (START-TKI)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05221372. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*